Literature DB >> 2532600

Recombinant soluble receptors for the Fc gamma portion inhibit antibody production in vitro.

N Varin1, C Sautès, A Galinha, J Even, P M Hogarth, W H Fridman.   

Abstract

The problem of the structural relationship between suppressive IgG-binding factor and low-affinity receptors for the Fc portion of IgG (Fc gamma RII) has not yet been solved. In the present work we have isolated a recombinant soluble Fc gamma RII containing only the two external domains of Fc gamma RII, and analyzed its biochemical characteristics and biological activity. A cDNA encoding Fc gamma RII was mutated by the creation of a stop codon at the Lys175 codon. L cells have been transfected with this cDNA inserted into an expression vector. A cell line was obtained that secretes recombinant soluble Fc gamma RII which reacts with a monoclonal anti-Fc gamma RII antibody and binds to IgG1, IgG2a and IgG2b murine isotypes but not to IgG3 or F(ab')2 fragments of IgG2a. The secreted molecule contains two molecular species of relative molecular mass (Mr) 44,000 and 34,000-38,000 and of pI 4.5 and 6.3. They correspond to different glycosylations of a single polypeptide of Mr 19,000. After purification to homogeneity, soluble Fc gamma RII has found to suppress secondary and primary in vitro antibody responses in a dose-dependent way. The present work shows that recombinant soluble Fc gamma RII has biochemical characteristics, immunoreactivity and biological activity similar to those of suppressive IgG-binding factor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2532600     DOI: 10.1002/eji.1830191213

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

Review 1.  Murine soluble Fc gamma receptors/IgG-binding factors (IgG-BF): analysis of the relation to Fc gamma RII and production of milligram quantities of biologically active recombinant IgG-BF.

Authors:  C Sautès; N Mazières; A Galinha; E Tartour; C Bonnerot; S Amigorena; C Teillaud; R Spagnoli; W H Fridman
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

2.  In vitro inhibition of tumor B cell growth by IgG-BF-producing Fc gamma RII+ T cell hybridoma and by immunoglobulin G-binding factors.

Authors:  C Mathiot; S Amigorena; J Moncuit; C Sautès; W H Fridman; J L Teillaud
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

3.  Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita.

Authors:  Hiroaki Iwata; Elena Pipi; Nicole Möckel; Peter Sondermann; Artem Vorobyev; Nina van Beek; Detlef Zillikens; Ralf J Ludwig
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

4.  The disulfide bridges of the immunoglobulin-like domains of Fc gamma RIIIB are essential for efficient expression and biological activity.

Authors:  B Enenkel; J Frey
Journal:  J Protein Chem       Date:  1993-08

5.  An alternative Fc gamma-receptor ligand: potential role in T-cell development.

Authors:  M Sandor; J Galon; L Takacs; Y Tatsumi; A L Mueller; C Sautes; R G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 6.  Receptors for gammaglobulin in the central and peripheral nervous system.

Authors:  C Vedeler; E Ulvestad; H Nyland; R Matre; J A Aarli
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

7.  N-glycan structures of a recombinant mouse soluble Fcgamma receptor II.

Authors:  N Takahashi; W Yamada; K Masuda; H Araki; Y Tsukamoto; A Galinha; C Sautès; K Kato; I Shimada
Journal:  Glycoconj J       Date:  1998-09       Impact factor: 2.916

8.  Increased levels of soluble low-affinity Fc gamma receptors (IgG-binding factors) in the sera of tumour-bearing mice.

Authors:  A Lynch; E Tartour; J L Teillaud; B Asselain; W H Fridman; C Sautès
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

Review 9.  Regulation of the expression of murine alpha- and beta-Fc gamma R genes.

Authors:  M Daëron
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

Review 10.  The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases.

Authors:  Peter Sondermann
Journal:  J Clin Immunol       Date:  2016-04-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.